Kunming Longjin Pharmaceutical Co Ltd (002750) — Working Capital to Net Assets Ratio
Kunming Longjin Pharmaceutical Co Ltd (002750) has a Working Capital to Net Assets ratio of 56.0% as of March 2025. Working capital of CN¥271.92 Million (current assets of CN¥311.11 Million minus current liabilities of CN¥39.19 Million) is measured against net assets of CN¥485.19 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See debt-free asset ratio of Kunming Longjin Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Kunming Longjin Pharmaceutical Co Ltd Working Capital to Net Assets (2011–2024)
This chart shows how Kunming Longjin Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of March 2025, the ratio stands at 56.0%, reflecting working capital of CN¥271.92 Million against net assets of CN¥485.19 Million CNY. Check how tangible is Kunming Longjin Pharmaceutical Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Kunming Longjin Pharmaceutical Co Ltd (002750) market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 58.6% | CN¥289.54 Million | CN¥494.21 Million | CN¥338.18 Million | CN¥48.63 Million | ▼ -3.1 pp |
| 2023 | 61.7% | CN¥333.92 Million | CN¥541.13 Million | CN¥384.06 Million | CN¥50.14 Million | ▼ -1.7 pp |
| 2022 | 63.4% | CN¥383.38 Million | CN¥604.77 Million | CN¥471.04 Million | CN¥87.66 Million | ▲ +3.0 pp |
| 2021 | 60.4% | CN¥409.37 Million | CN¥678.29 Million | CN¥522.77 Million | CN¥113.40 Million | ▲ +0.8 pp |
| 2020 | 59.5% | CN¥419.33 Million | CN¥704.71 Million | CN¥519.61 Million | CN¥100.28 Million | ▲ +3.3 pp |
| 2019 | 56.2% | CN¥374.23 Million | CN¥665.89 Million | CN¥479.48 Million | CN¥105.25 Million | ▼ -0.7 pp |
| 2018 | 56.9% | CN¥373.13 Million | CN¥655.93 Million | CN¥472.57 Million | CN¥99.43 Million | ▲ +0.1 pp |
| 2017 | 56.8% | CN¥366.79 Million | CN¥645.54 Million | CN¥478.67 Million | CN¥111.89 Million | ▼ -1.1 pp |
| 2016 | 57.9% | CN¥388.23 Million | CN¥670.46 Million | CN¥449.76 Million | CN¥61.53 Million | ▲ +0.1 pp |
| 2015 | 57.8% | CN¥346.54 Million | CN¥599.41 Million | CN¥416.59 Million | CN¥70.05 Million | ▲ +53.8 pp |
| 2014 | 4.0% | CN¥11.42 Million | CN¥285.57 Million | CN¥136.50 Million | CN¥125.08 Million | ▲ +2.9 pp |
| 2013 | 1.1% | CN¥3.44 Million | CN¥302.00 Million | CN¥122.49 Million | CN¥119.05 Million | ▲ +4.0 pp |
| 2012 | -2.8% | CN¥-6.43 Million | CN¥226.94 Million | CN¥122.70 Million | CN¥129.13 Million | ▼ -12.3 pp |
| 2011 | 9.5% | CN¥17.73 Million | CN¥186.74 Million | CN¥107.85 Million | CN¥90.12 Million | — |